1244OKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. (23rd October 2018) - Ascierto, P A; Ferrucci, P F; Stephens, R; Del Vecchio, M; Atkinson, V; Schmidt, H; Schachter, J; Queirolo, P; Long, G V; Di Giacomo, A M; Svane, I; Lotem, M; et al.